2026年2月5日 / 美国东部时间晚上8:19 / 哥伦比亚广播公司新闻
特朗普政府于周四晚间推出了新的特朗普处方药（TrumpRx）药品清单网站，这是特朗普总统推动降低直接面向消费者药品价格的举措之一。
总统去年与十多家制药商达成协议，将其部分药物以远低于标价的折扣价列入TrumpRx，辉瑞（Pfizer）和诺和诺德（Novo Nordisk）等大型公司——以减肥和糖尿病药物司美格鲁肽（Ozempic）和韦戈维（Wegovy）闻名——均已签约。
该网站列出了数十种降价的处方药。例如，一个月疗程的韦戈维注射笔头两个月售价199美元，之后为349美元，远低于1,349.02美元的标价。诺和诺德近几周通过其NovoCare药房项目也以类似折扣价提供韦戈维。
用于体外受精（IVF）过程的常见药物果纳芬（Gonal-F）的一种剂型在TrumpRx上售价252美元，较标价折扣83%。特朗普在竞选活动中承诺确保生育治疗由私人保险或政府全额覆盖。
该网站不直接销售药品——相反，用户被引导打印带有金边的优惠券，网站称可在药店使用。
周四晚间的白宫活动中，特朗普总统称这是”有史以来最具变革性的医疗保健举措之一”。政府首席设计官乔·吉比亚（Joe Gebbia）——Airbnb联合创始人，参与了该网站的设计——表示，随着时间推移，更多药物将被添加到TrumpRx中。
目前尚不清楚TrumpRx会对大多数美国人支付的处方药价格产生多大影响。
大多数人通过保险支付药品费用，而非自付，因此TrumpRx提供的折扣可能不会改变他们的支出。该网站指出：”如果您有保险，请先查看自付额——它可能更低。”
华盛顿大学卫生经济学家肖恩·沙利文（Sean Sullivan）去年告诉哥伦比亚广播公司新闻：”在我看来，直接面向患者的内容更多是为特朗普做宣传和品牌建设的机会。大多数患者都有药品保险…除非药物不在保险覆盖范围内，如减肥或勃起功能障碍药物，否则很少有人会用现金购买药品。”
但对于未参保的美国人、高免赔额人群以及药品未被保险覆盖的患者——包括一些减肥和IVF药物使用者——大幅折扣的直接面向消费者的选项可能会产生影响。
美国医疗保险和医疗补助服务中心管理员梅赫梅特·奥兹（Mehmet Oz）博士周四表示：”从现在开始，您在购买药品前，至少应该查看这些药物是否有折扣价可用。”
特朗普总统数月来一直向制药商施压，要求削减药品价格。
除了TrumpRx之外，他还与多家制药公司达成协议，以最惠国价格向医疗补助患者提供其药物，这意味着他们不能收取高于其他高收入国家患者支付的价格。这些公司还同意对在美国推出的新药提供最惠国定价。
美国人往往支付远高于欧洲同行的药品价格，这长期以来困扰着两党成员。多年来，立法者提议对美国药品价格设限或与国外价格挂钩，但制药公司通常予以抵制，警告称价格上限可能会增加新药研发的资金负担。
总统周四表示：”长期以来，美国人支付着世界上最高的药品价格，而其他国家为完全相同的药物只支付微不足道的费用。我们基本上在补贴整个世界。”
药品定价专家告诉哥伦比亚广播公司新闻，制药公司通常在每年年初提高价格，2026年也不例外。
根据药品定价研究非营利组织46brooklyn的数据，今年1月，制造商将947种品牌药的标价提高，仅降低了20种的价格。品牌药的标价——即制药商在协商回扣或其他折扣前设定的”标价”——在2026年迄今为止的平均涨幅为4%，与去年的增幅持平。
过去十年中，由于公众对高药价的反对，年度涨价幅度有所下降，但去年的涨幅仍超过了通胀率。
46brooklyn的数据确实显示，在少数情况下，常用药物的标价大幅下降。血液稀释剂Eliquis的标价暴跌43%，而用于治疗2型糖尿病的Jardiance降价44%。这两种药物均为拜登政府根据《通胀削减法案》选定的首批10种接受医疗保险价格谈判的药物。
追踪交易成本而非标价的处方药消费者价格指数（CPI）在2024年12月至2025年12月期间上涨了2%。自2025年1月特朗普开始第二任期以来，该指数下降了不到1%。
赛琳·贡德尔（Céline Gounder）博士对本文亦有贡献。
White House launches TrumpRx discounted drug site
February 5, 2026 / 8:19 PM EST / CBS News
The Trump administration launched its new TrumpRx prescription drug listing site late Thursday, part of a push by President Trump to offer lower direct-to-consumer drug prices.
The president struck deals last year with more than a dozen drugmakers to list some of their medication on TrumpRx at steep discounts from list prices, with megacompanies like Pfizer and Novo Nordisk — known for weight loss and diabetes drugs Ozempic and Wegovy — signing on.
The site lists dozens of prescription drugs at reduced rates. For example, a four-week supply of Wegovy injection pens is listed at $199 for the first two months and $349 after that, well below the list price of $1,349.02. Novo Nordisk has offered Wegovy for similarly discounted prices through its NovoCare Pharmacy program in recent weeks.
A unit of Gonal-F, a common drug used as part of the in vitro fertilization (IVF) process, is listed on TrumpRx at $252, an 83% discount from the sticker price. Mr. Trump pledged on the campaign trail to ensure that fertility treatments are fully covered either by private insurance or the government.
The site does not sell drugs directly — instead, users are prompted to print out a gold-embossed coupon that it says can be used at pharmacies.
In a White House event Thursday evening, Mr. Trump called it “one of the most transformative health care initiatives of all time.” The administration’s Chief Design Officer Joe Gebbia, an Airbnb founder who helped design the site, said more drugs will be added to TrumpRx over time.
It’s not clear how much of an impact TrumpRx will have on the prices most Americans pay for prescription drugs.
Most people pay for their medication through insurance rather than out-of-pocket, so the discounts offered by TrumpRx may not change what they pay. The site notes: “If you have insurance, check your co-pay first—it may be even lower.”
“The direct-to-patient stuff is, in my view, a sideshow and branding opportunity for Trump,” Sean Sullivan, a health economist at the University of Washington, told CBS News last year. “Most patients have drug coverage. … Very few are going to buy medications with cash, unless the drug is not a covered benefit, like weight loss or erectile dysfunction drugs.”
But steeply discounted direct-to-consumer options could matter for uninsured Americans, people with high deductibles and patients whose medications aren’t covered by their insurance — including some users of weight loss and IVF drugs.
“You should not be buying drugs anymore, going forward, without at least checking to see if those medications are available at these discounted prices,” Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services, said Thursday.
Mr. Trump has pressed drugmakers for months to slash their prices.
Beyond TrumpRx, he has cut deals with several pharmaceutical companies to offer their drugs to Medicaid patients at most-favored-nation prices, meaning they cannot charge more than the prices paid by people in other high-income countries. The companies also agreed to offer most-favored-nation pricing for new drugs introduced in the U.S.
The fact that Americans tend to pay far higher drug prices than their European peers has long vexed members of both parties. For years, lawmakers have proposed capping U.S. drug prices or tying them to the prices paid in foreign countries, though pharmaceutical companies have typically pushed back, warning that price caps could make it harder to pay for research into new drugs.
“Americans have long been paying the highest drug prices anywhere in the world while other countries often paid pennies on the dollar for the exact same drugs,” the president said Thursday. “We were essentially subsidizing the entire world.”
Pharmaceutical companies routinely raise prices at the beginning of each year, and 2026 has been no exception, drug pricing experts told CBS News.
Manufacturers raised list prices of 947 brand-name drugs this January, while lowering prices on 20, according to drug pricing research nonprofit 46brooklyn. The list prices for brand-name drugs — which are like the sticker prices set by drugmakers before rebates or other discounts are negotiated — increased by a median of 4% so far in 2026, on par with last year’s increase.
The size of annual increases has fallen in the last decade amid public backlash over high drug costs, but last year’s increases still outpaced the inflation rate.
Data from 46brooklyn does show that in a few cases, list prices for widely used drugs have fallen substantially. The list price of Eliquis, a blood thinner, plunged 43%, while Jardiance, used to treat Type 2 diabetes, fell 44%. Both drugs were among the first 10 medications selected for Medicare price negotiations through a Biden-era provision in the Inflation Reduction Act.
The Consumer Price Index for prescription drugs — which tracks transaction costs rather than list prices — has also risen 2% between December 2024 and December 2025. And since January 2025, when Mr. Trump was inaugurated for his second term, the index has declined by less than 1%.
Dr. Céline Gounder contributed to this report.